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A B S T R A C T   
Background: The purpose of this study is to assess how the COVID-19 pandemic affected cancer screening at a large tertiary care setting in the city of Karachi, the third 
largest city in the world, and to identify if there has been any decrease in cancer screening during the ongoing pandemic. 
Methods: A retrospective observational study was conducted at the clinical chemistry laboratory at the Department of Pathology & Laboratory Medicine, Aga Khan 
University Hospital (AKUH), Karachi Pakistan. Data for test volumes was extracted from the Integrated Laboratory Management System (ILMS) for the following 
tumor markers: CA19 Carbohydrate Antigen 19-9 (CA 19-9), Calcitonin, Prostate Specific Antigen (PSA), from 2017 to 2020. Data from January 1st, 2017 till 
December 31st, 2019 was recorded and compared with the test volume data from January 1st, 2020 till December 31st, 2020. Number of tests performed in the prior 
3 years were compared with tests performed in 2020, specifically looking at changes during the lockdown period in 2020 (1st March – 9 th April) and compared with 
the same period in preceding years. 
Results: During the four-year period, a total of 6,530 tests were performed for CA19-9, 893 for Calcitonin, and 54,769 for PSA. Year 2019 recorded the highest volume 
for all 3 tests with test volumes increasing continuously from 2017 to 2019. Number of tests performed decreased throughout the year 2020 for Calcitonin and PSA, 
whereas volume of tests for CA19-9 only reduced during the lockdown period while increased in the non-lockdown period as compared to previous years. Highest 
percent decline during the 2020 lockdown period was seen for Calcitonin (-62.5%), followed by PSA (-51.8%) and CA19-9 (-19%). 
Conclusion: In conclusion, the amount of CA19-9, Calcitonin, and PSA tests performed in Karachi, Pakistan has drastically reduced due to the lockdown that was 
mandated due to the COVID-19 outbreak. It is crucial that despite an imposed lockdown, regular cancer screening must continue.   
1. Introduction 
COVID-19 pandemic has caused unprecedented morbidity and 
mortality globally [1]. Though the direct effects of COVID-19 are well 
studied and documented, the indirect losses incurred financially, and 
non-COVID related health issues are remain under-reported [2]. The 
lockdowns imposed by the governments to curb the spread of the disease 
resulted in significant financial losses in terms of businesses, jobs and 
travel restrictions. Although some of these losses were predicted be-
forehand and prepared for, healthcare sector, apart from COVID-19, is 
one area that may have been overlooked. 
Literature suggests multi-faceted consequences of COVID-19, 
including exacerbation of pre-existing diseases [3]. One of the disease 
groups where the effects of pandemic could be particularly detrimental 
is cancer, specifically cancer screening. With over 19 million new cancer 
cases in 2020 and almost 10 million cancer deaths; this group cannot be 
overlooked irrespective of the pandemic situation [4]. COVID-19 
pandemic could be harmful for such patients if it results in delayed di-
agnoses and/or treatment. Travel restrictions, lockdowns imposed by 
governments and general fear of visiting hospitals during acute rise in 
COVID-19 cases may interfere with diagnosis and treatment of cancer 
patients. Specially for cancer screening, delayed diagnosis can lead to 
advanced tumor stages at first diagnosis, which leads to poorer treat-
ment outcomes and increased morbidity and mortality in such patients 
[5]. Pakistan being a low-middle-oncome country (LMIC), where med-
ical resources are inadequate and healthcare facilities are scarce, maybe 
at an additional danger of delayed diagnosis of cancer patients. 
The purpose of this study is to assess how the COVID-19 pandemic 
affected cancer screening at a large tertiary care setting in the city of 
Karachi, the third largest city in the world, and to identify if there has 
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been any decrease in cancer screening during the ongoing pandemic. 
2. Methods 
A retrospective observational study was conducted at the clinical 
chemistry laboratory at the Department of Pathology & Laboratory 
Medicine, Aga Khan University Hospital (AKUH), Karachi Pakistan, 
which serves as a national reference lab for the country. With a large 
network of more than 290 phlebotomy centers and outreach laboratories 
spread across the country, it accommodates test requests from all the 
provinces. The laboratory operates to highest standards of quality and 
was the first lab to be accredited by College of American Pathologists 
(CAP) as well as Joint Commission International Accreditation (JCIA). 
Data for test volumes was extracted from the Integrated Laboratory 
Management System (ILMS) for the following tumor markers: CA19 
Carbohydrate Antigen 19–9 (CA 19–9), Calcitonin, Prostate Specific 
Antigen (PSA), from 2017 to 2020. 
Data from January 1st, 2017 till December 31st, 2019 was recorded 
and compared with the test volume data from January 1st, 2020 till 
December 31st, 2020. No patient-related information was gathered 
hence ethical approval was not required. 
Frequencies and means were calculated for the volume of tests per-
formed during the 4-year period. Number of tests performed in the prior 
3 years were compared with tests performed in 2020, specifically 
looking at changes during the lockdown period in 2020 (1st March – 9th 
April) and compared with the same period in preceding years. The 
changes in the number of tests performed were expressed in terms of 
percent change. Microsoft Excel 2019 was used for data analysis. 
3. Results 
During the four-year period, a total of 6530 tests were performed for 
CA19-9, 893 for Calcitonin, and 54,769 for PSA. Year 2019 recorded the 
highest volume for all 3 tests with test volumes increasing continuously 
from 2017 to 2019. Number of tests performed decreased throughout 
the year 2020 for Calcitonin and PSA, whereas volume of tests for CA19- 
9 only reduced during the lockdown period while increased in the non- 
lockdown period as compared to previous years. Highest percent decline 
during the 2020 lockdown period was seen for Calcitonin (− 62.5%), 
followed by PSA (− 51.8%) and CA19-9 (− 19%). The means of tests 
along during the lock down period and the non-lockdown period, along 
with the percent change are given in Table 1. 
4. Discussion 
The results of our study show a decrease in cancer screening tests 
during the pandemic, especially during the lockdown period. This could 
result in delayed diagnosis and treatment of cancer patients which can 
be detrimental for patients already facing a global catastrophe. 
The results are in-line with findings from other regions as well. Patt 
et al. performed a study in US population and reported that at the peak 
of pandemic in April 2020, screenings for breast, colon, prostate, and 
lung cancers were lower by 85%, 75%, 74%, and 56%, respectively [6]. 
They reported that institutional providers had greater reductions in 
delivery of cancer care. Similar results were reported by Ferrari et al. 
from Italy who reported a 62% decrease in PSA tests requests during the 
lockdown period [7]. 
Although the results in our study are in-line with the results from 
other regions; the consequences could be more severe for Pakistan due 
an already low cancer screening as compared to developed countries. 
The CA19-9 tests volumes, apart from the lockdown period, saw a 
rebound increase in 2020 as compared to previous years. This increase 
can be attributed to tests that were not performed during the lockdown 
period. Also, the tests performed each year has been continuously 
increasing from 2017 onwards. Surprisingly, no such rebound increase 
was seen for Calcitonin and PSA, which could be alarming, if the cancer 
screening was never performed on such patients. 
The overall decrease in cancer screening tests performed could be 
attributed to a number of reasons. One reason that could be the fear of 
leaving the house during the lockdown period. A study conducted March 
2020 in Karachi, Pakistan showed that 62.5% of respondents claimed to 
have feelings of anxiety due to the pandemic [8]. Another reason could 
be logistic difficulties due to closure of public transportation during 
lockdown. This made it harder for patients relying on public trans-
portation to access healthcare facilities [9]. Another reason may be 
possible confusion on whether testing services were still available. The 
pandemic caused many businesses and clinics to suspend operations. 
This may have led to assumption that cancer screening services were not 
available during the lockdown period [10]. The poverty level of Pakistan 
is projected to rise about 33.7% due to the pandemic [11]. This could 
also be a reason for decreased testing during the pandemic period. 
The limitation of our study is a single center design. Also, only 3 
cancer screening tests were studied. But this was a first of its kind study 
from Pakistan which can give insight about impact of COVID-19 on 
healthcare delivery in the region. The results of the study can be used to 
educate patients and healthcare providers about the potential gaps 
created in healthcare delivery and address them using structured 
educational approaches so essential health work in not missed. 
5. Conclusion 
In conclusion, the amount of CA19-9, Calcitonin, and PSA tests 
performed in Karachi, Pakistan has drastically reduced due to the 
lockdown that was mandated due to the COVID-19 outbreak. It is crucial 
that despite an imposed lockdown, regular cancer screening must 
continue. 
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Table 1 
Comparison of tests performed in 2020 with mean tests performed 2017–2019.   
Tests performed in 
2020 





Total period 1798 1577.33 12.3% 
Lockdown 
perioda 
145 179 ¡19% 
No lockdown 
period 
1653 1398.33 15.4% 
CALCITONIN 
Total period 211 227.33 ¡7.2% 
Lockdown 
perioda 
12 32 ¡62.5% 
No lockdown 
period 
199 195.33 1.8% 
PSA 
Total period 12778 13997 ¡8.7% 
Lockdown 
perioda 
759 1576 ¡51.8% 
No lockdown 
period 
12019 12421 ¡3.2%  
a Lockdown period was between March 1 and April 9, 2020. 
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